That was highlighted by strong global sales for the companys essential brands.

Bristol-Myers Squibb reviews second quarter 2014 financial results Bristol-Myers Squibb Business has reported financial results for the next quarter of 2014, that was highlighted by strong global sales for the company’s essential brands; the accomplishment of important regulatory milestones for essential brands in Japan, Europe and the U buy prescription drugs online .S.; a fresh strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; and the initiation of several research collaborations that will fortify the company’s leadership position in immuno-oncology. Furthermore, the ongoing company adjusted 2014 GAAP guidance and confirmed 2014 non-GAAP guidance.

Bristol-Myers Squibb to provide new immunotherapy research data in ASCO Annual Meeting Bristol-Myers Squibb Firm today announced that new data from research investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung malignancy and metastatic renal cell carcinoma will be presented in the 50th Annual Conference of the American Culture of Clinical Oncology in Chicago from May 30-June 3. Bristol-Myers Squibb offers been at the forefront of research and discovery in the field of immuno-oncology and these data add to the growing body of research from its leading immuno-oncology pipeline, additional helping the scientific rationale for the potential of these checkpoint inhibitors as one agents or as part of a combination program.

Other Posts From Category "urology":

Related Posts